A 6-month study of the effects of 0.3% triclosan/copolymer dentifrice on dental implants.
OBJECTIVE
Supportive therapy to maintain dental implants is increasingly important. This study examined the effect of a 0.3% triclosan/2% copolymer dentifrice on oral biofilms and gingival inflammation (GI) on dental implants and peri-implant tissues.


METHODS
One hundred and twenty adults with a dental implant and contra-lateral tooth were enrolled in this 6 month, double-blind, two-treatment, parallel group study. Sixty subjects were randomly assigned to a triclosan/copolymer dentifrice test group and 60 subjects to a fluoride dentifrice control group and instructed to brush twice daily for 6 months. At baseline, 3, and 6 months, a calibrated dentist assessed dental plaque, GI and collected supragingival dental plaque for microbiological analysis.


RESULTS
Subjects in the triclosan/copolymer group demonstrated significantly lower levels of dental plaque, gingivitis, and bleeding on probing at 3 and 6 months at both the implant and contra-lateral tooth compared with the fluoride group (p<0.05). There were significantly fewer Gram-negative anaerobes in the triclosan/copolymer group (p<0.05) including >90% reductions in Aggregatibacter actinomycetemcomitans, Campylobacter rectus, Eubacterium saburreum, Fusobacterium nucleatum, Porphyromonas gingivalis, Prevotella melaninogenica, Solobacterium moorei, and Tannerella forsythia.


CONCLUSIONS
Twice daily use of a triclosan/copolymer dentifrice may enhance dental implant maintenance by reducing dental plaque and GI.
Sreenivasan
Prem K
PK
Clinical Dental Research, Colgate Palmolive, Piscataway, NJ, USA.
Vered
Yuval
Y
Zini
Avi
A
Mann
Jonathan
J
Kolog
Hilla
H
Steinberg
Doron
D
Zambon
Joseph J
JJ
Haraszthy
Violet I
VI
da Silva
Maike P
MP
De Vizio
William
W
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001419:Bacteria / Q000187:drug effects; D018441:Biofilms / Q000187:drug effects*; D015169:Colony Count, Microbial; D004269:DNA, Bacterial / Q000032:analysis; D015921:Dental Implants / Q000382:microbiology*; D003773:Dental Plaque / Q000382:microbiology / Q000517:prevention & control; D003802:Dentifrices / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D005459:Fluorides / Q000494:pharmacology / Q000627:therapeutic use; D005891:Gingivitis / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008298:Maleates / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D057873:Peri-Implantitis / Q000517:prevention & control; D010512:Periodontal Index; D011145:Polyvinyls / Q000494:pharmacology / Q000627:therapeutic use*; D016459:Prosthesis-Related Infections / Q000517:prevention & control; D014260:Triclosan / Q000494:pharmacology / Q000627:therapeutic use*; D055815:Young Adult
D004269:DNA, Bacterial; D015921:Dental Implants; D003802:Dentifrices; D004338:Drug Combinations; D008298:Maleates; D011145:Polyvinyls; C058026:polyvinylmethoxyethylene-maleic anhydride copolymer; D014260:Triclosan; D005459:Fluorides